Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: GlobeNewswire
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled “An A3 adenosine receptor ligand for use for achieving a fat loss effect. The patent covers the use of Namodenoson, Can-Fite’s orally bioavailable A3 adenosine receptor (A3AR) agonist, for reducing fat mass and body weight, providing intellectual property protection in Canada for its development as an anti-obesity therapy. Can-Fite already holds corresponding patents in the United States and Australia for the use of Namodenoson in obesity and metabolic disorders. Na
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of NamodenosonGlobeNewswire
- Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with NamodenosonGlobeNewswire
- Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson [Yahoo! Finance]Yahoo! Finance
- Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of NamodenosonGlobeNewswire
- Can-Fite Granted Brazilian Patent for Treatment of Sexual DysfunctionGlobeNewswire
CANF
Sec Filings
- 2/17/26 - Form 6-K
- 2/9/26 - Form 6-K
- 2/5/26 - Form 6-K
- CANF's page on the SEC website